Human Umbilical Cord Mesenchymal Stem Cells Treatment in Sepsis

Launched by DAPING HOSPITAL AND THE RESEARCH INSTITUTE OF SURGERY OF THE THIRD MILITARY MEDICAL UNIVERSITY · Mar 17, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a potential new treatment for sepsis, a serious condition caused by infections that can lead to organ failure. Researchers want to see if using special stem cells from human umbilical cords can help improve survival rates in people with sepsis. The trial will look at how effective these stem cells are over 28 days and also assess how safe they are for patients.

To participate in this trial, you must be between 0 and 65 years old and diagnosed with sepsis according to specific medical guidelines. Unfortunately, not everyone will be eligible; for example, people with certain serious health issues, those who are pregnant, or anyone currently taking part in other clinical trials will not be able to join. If eligible, participants can expect to receive an intravenous infusion of stem cells and will be monitored closely for safety and effectiveness. This trial aims to gather important information that could help develop new treatments for sepsis in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age: 0-65 years old, diagnosed with sepsis
• • Clinical diagnosis of sepsis (based on Sepsis 3.0 International Guidelines)
• • Confirmed or suspected infection
• Exclusion Criteria:
• • Violation of medical ethics
• • Significant confounding factors likely to bias study outcomes
• • Poor adherence to the study protocol
• • Concurrent participation in other clinical trials
• * Specific medical conditions:
• • 1. History of chronic enteritis, neuropsychiatric disorders, or transplantation (bone marrow, lung, liver, pancreas, or small intestine)
• • 2. Severe primary diseases affecting survival (e.g., life-limiting hepatic, renal, or endocrine disorders) or psychiatric disorders
• • 3. History of hypersensitivity or severe adverse reactions to biological products
• • 4. Imminent terminal status (e.g., septic shock, life expectancy \<7 days)
• • 5. Foreseeable risk of medical errors or disputes during hospitalization
• • 6. Active drug-resistant infections
• • 7. History of malignancy at screening
• • 8. Pregnancy, lactation, or plans for pregnancy within the next year